Role of TRAILR1 and TNFR1A polymorphisms in the susceptibility and pharmacogenetics of rheumatoid arthritis and ankylosing spondylitis patients treated with infliximab
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1479-5876
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Role of TRAILR1 and TNFR1A polymorphisms in the susceptibility and pharmacogenetics of rheumatoid arthritis and ankylosing spondylitis patients treated with infliximab ; volume:8 ; number:1 ; day:25 ; month:11 ; year:2010 ; pages:1 ; date:11.2010
Journal of translational medicine ; 8, Heft 1 (25.11.2010), 1, 11.2010
- Creator
-
Morales-Lara, M J.
- Contributor
-
Conesa-Zamora, P.
Santaclara, V.
Torres-Moreno, D.
Pedrero, F.
Corral, J.
Perez-Guillermo, M.
Rodríguez-Martínez, F J.
Soriano-Navarro, E.
SpringerLink (Online service)
- DOI
-
10.1186/1479-5876-8-S1-P50
- URN
-
urn:nbn:de:1111-2016041436174
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:51 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Morales-Lara, M J.
- Conesa-Zamora, P.
- Santaclara, V.
- Torres-Moreno, D.
- Pedrero, F.
- Corral, J.
- Perez-Guillermo, M.
- Rodríguez-Martínez, F J.
- Soriano-Navarro, E.
- SpringerLink (Online service)
Other Objects (12)
Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab
Infliximab-induced retrobulbar optic neuritis in a patient with ankylosing spondylitis
Body mass index influences the response to infliximab in ankylosing spondylitis
T cell responses to putative antigens and downregulation of cytokineproduction by infliximab in ankylosing spondylitis patients
Association between ankylosing spondylitis and m6A methylation
T-cell response to putative antigens and downregulation of cytokine production by infliximab in ankylosing spondylitis patients
T-cell responses to putative antigens and downregulation of cytokine production by infliximab in ankylosing spondylitis patients
Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis
Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study
Influence of a polymorphism IL1B gene in the response of rheumatoid arthritis and ankylosing spondylitis patients treated with infliximab
Andersson lesion in ankylosing spondylitis
Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study
Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab
Infliximab-induced retrobulbar optic neuritis in a patient with ankylosing spondylitis
Body mass index influences the response to infliximab in ankylosing spondylitis
T cell responses to putative antigens and downregulation of cytokineproduction by infliximab in ankylosing spondylitis patients
Association between ankylosing spondylitis and m6A methylation
T-cell response to putative antigens and downregulation of cytokine production by infliximab in ankylosing spondylitis patients
T-cell responses to putative antigens and downregulation of cytokine production by infliximab in ankylosing spondylitis patients
Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis
Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study
Influence of a polymorphism IL1B gene in the response of rheumatoid arthritis and ankylosing spondylitis patients treated with infliximab
Andersson lesion in ankylosing spondylitis
Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study
Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab
Infliximab-induced retrobulbar optic neuritis in a patient with ankylosing spondylitis
Body mass index influences the response to infliximab in ankylosing spondylitis
T cell responses to putative antigens and downregulation of cytokineproduction by infliximab in ankylosing spondylitis patients
Association between ankylosing spondylitis and m6A methylation
T-cell response to putative antigens and downregulation of cytokine production by infliximab in ankylosing spondylitis patients
T-cell responses to putative antigens and downregulation of cytokine production by infliximab in ankylosing spondylitis patients
Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis
Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study
Influence of a polymorphism IL1B gene in the response of rheumatoid arthritis and ankylosing spondylitis patients treated with infliximab
Andersson lesion in ankylosing spondylitis